MARKET

ATOS

ATOS

Atossa Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.080
+0.020
+0.97%
After Hours: 2.080 0 0.00% 16:00 09/20 EDT
OPEN
2.040
PREV CLOSE
2.060
HIGH
2.080
LOW
2.030
VOLUME
90.77K
TURNOVER
--
52 WEEK HIGH
7.39
52 WEEK LOW
0.8000
MARKET CAP
18.99M
P/E (TTM)
-0.8596
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATOS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ATOS News

  • Atossa Genetics Shares Volatile On Heavy Volume; Traders Circulate World Intellectual Property Organization Patentscope Application For 'In Situ Methods Of Inducing Of Immune Response'
  • Benzinga.2d ago
  • Atossa Genetics (ATOS) Investor Presentation - Slideshow
  • Seeking Alpha - Article.3d ago
  • Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference
  • GlobeNewswire.09/06 13:30
  • Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet
  • GlobeNewswire.09/03 13:00

More

Industry

Advanced Medical Equipment & Technology
-0.70%
Healthcare Equipment & Supplies
-0.22%

Hot Stocks

Name
Price
%Change

About ATOS

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.
More

Webull offers Atossa Genetics Inc (ATOS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.